On this page
Neuronal ceroid lipofuscinosis 3 (Batten, CLN3)
NCL3 is a progressive genetic disorder characterised by vision loss, seizures, and a decline in cognitive and motor skills. It typically affects children, leading to severe neurological impairment over time.
Available at Jeen Health
Clinical tests that include this
Overview
Neuronal ceroid lipofuscinosis type 3 (NCL3), often referred to as Batten disease, is a rare, inherited neurodegenerative disorder. It is part of a group of conditions known as neuronal ceroid lipofuscinoses (NCLs). NCL3 typically begins in childhood, usually between the ages of 4 and 10 years, and progressively worsens over time [PMID:31536338]. The condition affects the brain and other parts of the nervous system, leading to a decline in various functions.
Over time, children with NCL3 experience a range of symptoms, including vision loss, seizures, and problems with movement and speech. The disorder can also affect cognitive abilities, leading to learning difficulties and intellectual decline. Understanding the progression of NCL3 is important for managing the condition and supporting affected individuals and their families.
Symptoms & clinical features
The initial symptoms of NCL3 often involve changes in vision. Children may develop progressive vision impairment, which can lead to blindness [PMID:31536338]. This visual decline is typically one of the earliest noticeable signs of the condition.
As NCL3 progresses, other neurological symptoms emerge. Seizures are a common feature, varying in type and severity. Individuals may also experience difficulties with coordination and balance, leading to problems with walking and movement (ataxia). Speech development can be affected, and existing speech may deteriorate. Over time, cognitive function declines, impacting learning, memory, and overall intellectual ability. Behavioural changes, such as irritability or anxiety, may also be observed.
Muscle weakness and dystonia (sustained muscle contractions causing twisting or repetitive movements) can also develop, further affecting mobility and daily activities. These symptoms generally become more pronounced with age, significantly impacting the quality of life.
Video: Genetics 101
Affected organs
NCL3 primarily affects the brain and eyes. Within brain cells (neurons), a build-up of fatty substances called lipofuscins occurs. This accumulation interferes with normal cell function and eventually leads to cell death, causing the progressive neurological symptoms observed in NCL3.
The retina, the light-sensitive tissue at the back of the eye, is also significantly affected. Degeneration of retinal cells contributes to the early and progressive vision loss seen in individuals with NCL3. Other organs may not be directly affected, but the severe neurological impairment impacts overall bodily functions.
Risks & severity
NCL3 is a severe, progressive disorder. The age of onset is typically in early to mid-childhood, usually between 4 and 10 years old. The condition is uniformly progressive, meaning symptoms will worsen over time. The rate of progression can vary between individuals, but the overall trajectory leads to profound neurological impairment.
Unfortunately, NCL3 significantly reduces life expectancy. While the exact prognosis can vary, affected individuals often do not live into adulthood, with many succumbing to complications of the disease in their teenage years or early twenties [PMID:31536338]. The severity of symptoms, such as the frequency of seizures and the degree of cognitive decline, contributes to the overall prognosis.
Genetic causes
NCL3 is caused by pathogenic variants in the CLN3 gene [PMID:37517929]. This gene provides instructions for making a protein called battenin, which is thought to be located in the membranes of lysosomes within cells. Lysosomes are cellular compartments responsible for breaking down and recycling waste materials. While the precise role of battenin is not fully understood, it is believed to be essential for the proper functioning of lysosomes and for maintaining cellular health.
When there are pathogenic variants in the CLN3 gene, the battenin protein may be absent, non-functional, or improperly formed. This leads to the accumulation of waste products, specifically fatty substances called lipofuscins, within the lysosomes of cells, particularly in neurons. This build-up is toxic to the cells, leading to their damage and eventual death, which underlies the progressive neurological symptoms of NCL3.
- CLN3 CLN3 lysosomal/endosomal transmembrane protein, batteninThe CLN3 gene encodes a transmembrane protein, battenin, primarily located in lysosomes, which are critical for cellular waste processing and recycling.
Inheritance pattern
NCL3 is inherited in an autosomal recessive pattern. This means that for a child to develop the condition, they must inherit two copies of the altered CLN3 gene - one from each parent. Individuals who have one altered copy of the gene and one functional copy are known as carriers. Carriers typically do not show any symptoms of NCL3 because their one functional gene copy is sufficient to produce enough functional battenin protein.
When both parents are carriers of a pathogenic CLN3 variant, there is a 25% chance with each pregnancy that their child will inherit two altered gene copies and develop NCL3. There is a 50% chance that the child will be a carrier like their parents, and a 25% chance that the child will inherit two functional copies of the gene and not be affected or a carrier.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
A diagnosis of NCL3 is typically suspected based on the clinical symptoms, particularly the combination of progressive vision loss, seizures, and cognitive decline in childhood. Confirmation of the diagnosis usually involves genetic testing to identify pathogenic variants in the CLN3 gene. This testing can be arranged through an NHS Genomic Medicine Service (GMS) laboratory.
Referrals for genetic testing are often made by paediatricians, neurologists, or ophthalmologists who suspect an underlying genetic condition. The NHS offers genomic testing for NCL3 under various R-codes, such as R253 for inherited retinal disease or R336 for childhood onset progressive neurodegeneration, depending on the presenting symptoms. Genetic counsellors can provide further information and support throughout the diagnostic process.
Management & lifestyle
Currently, there is no cure for NCL3, and management focuses on supporting individuals and managing symptoms to improve their quality of life. This involves a multidisciplinary approach, often coordinated through paediatric services and specialist neurological teams within the NHS.
Treatments for symptoms may include anticonvulsant medications to help control seizures and therapies to address motor and speech difficulties, such as physiotherapy, occupational therapy, and speech and language therapy. Educational support and adaptive equipment can also be crucial as vision and cognitive abilities decline. Regular monitoring by healthcare professionals is important to manage emerging symptoms and complications. Research continues into potential new therapies, including gene therapy and enzyme replacement therapy.
UK care pathway
In the UK, individuals with suspected NCL3 typically enter the NHS Genomic Medicine Service pathway following a referral from a specialist clinician, such as a paediatrician or neurologist. Genetic testing is available through NHS GMS laboratories, often accessed via specific R-codes depending on the primary symptoms. Following diagnosis, care is managed by a multidisciplinary team, with access to clinical genetics services and genetic counsellors who can provide support and information to families.
Frequently asked questions
What is the typical age of onset for Batten disease (NCL3)?
Batten disease (NCL3) typically begins in childhood, with initial symptoms usually appearing between the ages of 4 and 10 years old. Vision loss is often one of the first noticeable signs.
Is there a cure for Batten disease (NCL3)?
Currently, there is no cure for Batten disease (NCL3). Management focuses on supportive care to manage symptoms and improve the individual's quality of life, using a multidisciplinary approach.
How is Batten disease (NCL3) diagnosed?
Diagnosis of Batten disease (NCL3) is typically based on clinical symptoms and confirmed through genetic testing to identify pathogenic variants in the CLN3 gene. This testing is available through NHS Genomic Medicine Service laboratories.
What does 'autosomal recessive inheritance' mean for NCL3?
Autosomal recessive inheritance for NCL3 means that a child must inherit a pathogenic copy of the CLN3 gene from both parents to develop the condition. Parents who carry one pathogenic gene copy typically do not have symptoms themselves.
Can Batten disease (NCL3) affect adults?
While NCL3 typically begins in childhood, it is a progressive disorder that can lead to severe complications in adolescence and early adulthood. There are also rarer forms of NCL that may have a later adult onset, but NCL3 itself is generally a childhood-onset condition.